CytomX Therapeutics Future Growth
Future criteria checks 0/6
CytomX Therapeutics's revenue and earnings are forecast to decline at 13.3% and 29.6% per annum respectively. EPS is expected to decline by 20.3% per annum. Return on equity is forecast to be -177.5% in 3 years.
Key information
-29.6%
Earnings growth rate
-20.3%
EPS growth rate
| Biotechs earnings growth | 21.3% |
| Revenue growth rate | -13.3% |
| Future return on equity | -177.5% |
| Analyst coverage | Good |
| Last updated | 22 Apr 2024 |
Recent future growth updates
Recent updates
CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
Apr 25CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%
Mar 05
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Jan 19There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise
Nov 26We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely
Nov 17Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 29Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?
Feb 13Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%
Nov 10CytomX Therapeutics to cut workforce by about 40%
Jul 13CytomX says phase 2 study of breast cancer antibody treatment met main goal
Jul 06Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Jun 08Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?
Feb 10CytomX: Pullbacks Are Opportunities
Dec 14CytomX: Solving A Critical Problem In The High-Value ADC Space
Sep 15We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate
Aug 11Checking In On CytomX Therapeutics
Jun 13Shareholders Will Probably Hold Off On Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For The Time Being
Jun 10CytomX EPS beats by $0.06, misses on revenue
May 06Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 11%
Mar 25Would Shareholders Who Purchased CytomX Therapeutics' (NASDAQ:CTMX) Stock Three Years Be Happy With The Share price Today?
Feb 02
How Much Of CytomX Therapeutics, Inc. (NASDAQ:CTMX) Do Institutions Own?
Dec 29Here's Why We're Not At All Concerned With CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Dec 03Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 46 | -71 | -13 | N/A | 3 |
| 12/31/2025 | 73 | -43 | -56 | -79 | 6 |
| 12/31/2024 | 94 | -24 | -52 | -28 | 5 |
| 12/31/2023 | 101 | -1 | -57 | -56 | N/A |
| 9/30/2023 | 95 | -10 | -36 | -35 | N/A |
| 6/30/2023 | 79 | -42 | -52 | -51 | N/A |
| 3/31/2023 | 68 | -71 | -61 | -60 | N/A |
| 12/31/2022 | 53 | -99 | -113 | -111 | N/A |
| 9/30/2022 | 21 | -149 | -142 | -141 | N/A |
| 6/30/2022 | 27 | -143 | -138 | -136 | N/A |
| 3/31/2022 | 30 | -132 | -132 | -130 | N/A |
| 12/31/2021 | 37 | -116 | -121 | -119 | N/A |
| 9/30/2021 | 66 | -72 | -107 | -105 | N/A |
| 6/30/2021 | 66 | -64 | -103 | -100 | N/A |
| 3/31/2021 | 67 | -61 | 23 | 25 | N/A |
| 12/31/2020 | 68 | -65 | 3 | 5 | N/A |
| 9/30/2020 | 92 | -54 | -9 | -7 | N/A |
| 6/30/2020 | 85 | -63 | -8 | -5 | N/A |
| 3/31/2020 | 78 | -76 | -154 | -151 | N/A |
| 12/31/2019 | 27 | -133 | -144 | -140 | N/A |
| 9/30/2019 | 61 | -99 | -144 | -140 | N/A |
| 6/30/2019 | 62 | -99 | -126 | -122 | N/A |
| 3/31/2019 | 75 | -83 | -105 | -100 | N/A |
| 12/31/2018 | 60 | -85 | -79 | -76 | N/A |
| 9/30/2018 | 75 | -52 | -28 | -25 | N/A |
| 6/30/2018 | 87 | -39 | -27 | -25 | N/A |
| 3/31/2018 | 74 | -50 | 173 | 175 | N/A |
| 12/31/2017 | 72 | -43 | 169 | 170 | N/A |
| 9/30/2017 | 51 | -58 | N/A | 150 | N/A |
| 6/30/2017 | 30 | -62 | N/A | 142 | N/A |
| 3/31/2017 | 24 | -51 | N/A | -16 | N/A |
| 12/31/2016 | 15 | -59 | N/A | -2 | N/A |
| 9/30/2016 | 11 | -57 | N/A | -12 | N/A |
| 6/30/2016 | 9 | -57 | N/A | -6 | N/A |
| 3/31/2016 | 8 | -50 | N/A | -28 | N/A |
| 12/31/2015 | 8 | -42 | N/A | -27 | N/A |
| 9/30/2015 | 8 | -36 | N/A | -24 | N/A |
| 6/30/2015 | 8 | -26 | N/A | 30 | N/A |
| 3/31/2015 | 6 | -24 | N/A | 31 | N/A |
| 12/31/2014 | 5 | -35 | N/A | 32 | N/A |
| 12/31/2013 | 1 | -19 | N/A | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CTMX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CTMX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CTMX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CTMX's revenue is expected to decline over the next 3 years (-13.3% per year).
High Growth Revenue: CTMX's revenue is forecast to decline over the next 3 years (-13.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CTMX is forecast to be unprofitable in 3 years.